BriaCell Therapeutics Corp.
BCTXHealthcare|Biotechnology|CA
$3.95
+0.68 (+20.80%)
DCF Value
$0.59
Tangible Book / Share
$1.77
Cash / Share
$2.36
Financials
Financial Snapshot
Market Cap
$34.5M
Enterprise Value
$24.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$38.3M
Cash & Investments
$20.5M
Net Cash
$20.5M
Free Cash Flow (TTM)
-$31.8M
Operating CF (TTM)
-$31.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$20.5M
Quarterly Burn
$7.9M
Monthly Burn
$2.6M
Est. Runway
~2.6 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.6M | $1.7M | $157.0K | $21.2K | $71.6M | $52.6M | $28.4M | $1.2M | $24.6M | $20.5M | $20.5M | |
| Operating Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$9.9M | -$15.9M | -$31.9M | -$33.0M | -$39.1M | -$28.7M | -$31.7M | |
| Free Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$9.9M | -$15.9M | -$31.9M | -$33.6M | -$39.1M | -$28.8M | -$31.8M | |
| Capital Expenditure | $4.00 | $3.00 | -$5.02 | $0.00 | -$4.27 | $0.00 | $3.59 | -$624.2K | $3.08 | -$127.0K | -$129.5K | |
| Financing Cash Flow | $2.9M | $5.3M | $3.0M | $1.4M | $82.9M | -$4.8M | $5.3M | $6.0M | $63.0M | $31.4M | $31.7M |
R&D Spending
R&D (TTM)
$34.1M
R&D Intensity
—
R&D Growth vs Prior
+16.5%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.1M | $3.1M | $4.9M | $3.0M | $2.5M | $10.3M | $20.5M | $27.2M | $29.5M | $29.2M | $34.1M | |
| SG&A | $1.1M | $1.8M | $1.3M | $1.8M | $6.2M | $9.3M | $10.6M | $6.2M | $8.1M | $6.8M | $8.0M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $289.71 | $16.9K | $18.8K | $18.7K | $15.6K | $15.1K | $15.5K | $82.6K | $147.9K | $117.9K | $86.4K | |
| Gross Profit | -$289.00 | -$16.9K | -$18.8K | -$18.7K | -$15.6K | -$15.1K | -$15.5K | -$82.6K | -$147.9K | -$117.9K | -$86.4K | |
| R&D | $2.1M | $3.1M | $4.9M | $3.0M | $2.5M | $10.3M | $20.5M | $27.2M | $29.5M | $29.2M | $34.1M | |
| SG&A | $1.1M | $1.8M | $1.3M | $1.8M | $6.2M | $9.3M | $10.6M | $6.2M | $8.1M | $6.8M | $8.0M | |
| Operating Income | -$3.2M | -$5.0M | -$6.3M | -$5.3M | -$8.7M | -$19.6M | -$31.1M | -$33.3M | -$37.7M | -$35.6M | -$39.5M | |
| Interest Expense | $0.00 | $20.3K | $31.5K | $36.2K | $100.2K | $1.2K | $0.00 | $0.00 | $51.3K | $0.00 | $29.6K | |
| Pretax Income | -$3.2M | -$5.4M | -$5.8M | -$5.4M | -$17.3M | -$34.4M | -$27.1M | -$4.9M | -$36.8M | -$34.9M | -$38.7M | |
| Net Income | -$3.2M | -$5.4M | -$5.8M | -$4.9M | -$17.3M | -$34.4M | -$27.1M | -$4.8M | -$36.5M | -$34.9M | -$38.3M | |
| EPS (Diluted) | -1348.63 | -1798.34 | -1505.30 | -5.64 | -13.50 | -259.50 | -195.00 | -43.01 | -62.60 | -6.97 | -9.38 | |
| EBITDA | -$3.2M | -$5.4M | -$5.8M | -$4.8M | -$17.2M | -$34.4M | -$31.1M | -$4.8M | -$37.6M | -$35.5M | -$38.9M | |
| Shares Out. (M) | 0.02 | 0.03 | 0.04 | 0.05 | 0.30 | 1.03 | 1.04 | 1.10 | 1.88 | 5.01 | 8.71 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.0M | $720.3K | $157.0K | $21.2K | $71.6M | $52.6M | $28.4M | $1.2M | $14.4M | $9.9M | $9.9M | |
| Short-Term Investments | $601.8K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.1M | $10.7M | $10.7M | |
| Total Current Assets | $1.6M | $1.9M | $168.5K | $261.5K | $72.2M | $54.3M | $36.0M | $5.1M | $27.4M | $22.0M | $22.0M | |
| Total Assets | $1.6M | $2.3M | $444.7K | $522.3K | $72.5M | $54.6M | $36.3M | $8.2M | $29.8M | $23.6M | $23.6M | |
| Total Current Liabilities | $885.9K | $1.3M | $1.1M | $4.0M | $695.9K | $1.2M | $2.4M | $10.4M | $5.5M | $8.0M | $8.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $32.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $885.9K | $1.3M | $1.1M | $4.1M | $38.0M | $41.4M | $41.3M | $11.9M | $5.9M | $8.0M | $8.0M | |
| Stockholders' Equity | $750.2K | $945.0K | -$688.7K | -$3.6M | $34.6M | $13.2M | -$5.0M | -$3.3M | $24.6M | $16.4M | $16.4M | |
| Retained Earnings | -$6.7M | -$9.7M | -$14.7M | -$18.2M | -$36.4M | -$77.4M | -$107.7M | -$118.6M | -$153.7M | -$146.7M | -$146.7M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$9.9M | -$15.9M | -$31.9M | -$33.0M | -$39.1M | -$28.7M | -$31.7M | |
| Capital Expenditure | $4.00 | $3.00 | -$5.02 | $0.00 | -$4.27 | $0.00 | $3.59 | -$624.2K | $3.08 | -$127.0K | -$129.5K | |
| Free Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$9.9M | -$15.9M | -$31.9M | -$33.6M | -$39.1M | -$28.8M | -$31.8M | |
| Investing Cash Flow | $149.8K | -$590.5K | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | -$931.7K | -$10.6M | -$3.8M | -$4.2M | |
| Financing Cash Flow | $2.9M | $5.3M | $3.0M | $1.4M | $82.9M | -$4.8M | $5.3M | $6.0M | $63.0M | $31.4M | $31.7M | |
| Issuance of Stock | $2.9M | $4.1M | $3.0M | $1.4M | $83.3M | $8.2M | $5.4M | $6.0M | $63.0M | $31.4M | $31.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$12.9M | -$63.5K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $1.1M | $0.00 | $27.6K | -$421.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.7M | $718.1K | |
| Net Change in Cash | $1.1M | -$377.7K | -$757.2K | -$170.6K | $71.5M | -$20.8M | -$26.3M | -$28.2M | $13.2M | -$618.3K | -$3.5M |
Dilution Tracker
Shares outstanding grew 1563.1% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+1563.1%
Stock Issuance (TTM)
$31.7M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.02 | 0.03 | 0.04 | 0.05 | 0.30 | 1.03 | 1.04 | 1.10 | 1.88 | 5.01 | 8.71 | |
| Change vs Prior % | — | 25.9% | 35.5% | 23.2% | 533.1% | 242.8% | 0.8% | 5.3% | 71.7% | 166.0% | 73.8% | |
| Stock Issuance | $2.9M | $4.1M | $3.0M | $1.4M | $83.3M | $8.2M | $5.4M | $6.0M | $63.0M | $31.4M | $31.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$12.9M | -$63.5K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.7M | $718.1K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -428.9% | -572.2% | 844.8% | 137.4% | -49.9% | -259.8% | 537.5% | 144.9% | -148.4% | -212.8% | -170.7% | |
| ROA % | -196.6% | -236.7% | -1308.4% | -946.3% | -23.8% | -63.0% | -74.7% | -58.8% | -122.6% | -148.0% | -147.3% | |
| ROIC % | -428.5% | -240.7% | 1707.7% | 165.3% | -12.1% | -36.7% | -91.8% | 1511.6% | -155.3% | -228.3% | -230.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 84.0% | -5739.8% | -11.6% | 0.5% | 16.8% | 2.8% | -2.6% | -431.7% | -79.1% | 20.3% | |
| Operating Income | -46.5% | -54.6% | -25.8% | 15.6% | -65.2% | -125.0% | -58.5% | -7.3% | -13.2% | 5.6% | |
| Net Income | -44.2% | -68.1% | -7.6% | 15.0% | -249.3% | -99.3% | 21.2% | 82.3% | -661.4% | 4.4% | |
| EPS (Diluted) | 0.9% | -33.3% | 16.3% | 99.6% | -139.4% | -1822.2% | 24.9% | 77.9% | -45.5% | 88.9% | |
| Operating Cash Flow | -21.1% | -159.2% | -3.3% | 69.6% | -536.0% | -60.5% | -100.9% | -3.4% | -18.5% | 26.7% | |
| Free Cash Flow | -21.1% | -159.2% | -3.3% | 69.6% | -536.0% | -60.5% | -100.9% | -5.3% | -16.3% | 26.3% | |
| R&D Expense | 123.1% | 46.4% | 58.9% | -39.7% | -15.2% | 307.3% | 99.1% | 32.7% | 8.5% | -0.9% | |
| SG&A Expense | -12.0% | 69.2% | -30.0% | 42.4% | 236.5% | 50.5% | 13.7% | -41.9% | 31.3% | -15.6% | |
| Total Assets | 95.8% | 39.7% | -80.5% | 17.5% | 13787.9% | -24.7% | -33.6% | -77.5% | 265.1% | -20.8% | |
| Book Value / Share | -19.1% | 0.0% | -153.8% | -324.2% | 251.8% | -88.8% | -137.8% | 29.9% | 472.3% | -75.5% | |
| Debt | 0.0% | 0.0% | -71.2% | -22.5% | -87.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 17.8% | 25.9% | 35.5% | 23.2% | 533.1% | 242.8% | 0.8% | 5.3% | 71.7% | 166.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.10
10Y Low / Med / High0.57 / 74.98 / 230.54
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.59
Tangible Book / Share
$1.77
Net Current Assets / Share
$1.61
Graham Net-Net
$1.44
Cash / Share
$2.36
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.66 | -3.28 | -1.89 | -256.55 | -56.44 | -3.73 | -5.21 | -2.62 | -0.12 | -0.49 | -0.42 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 230.54 | 178.23 | -159.88 | -19.14 | 6.64 | 74.98 | -207.15 | -37.44 | 0.57 | 1.05 | 2.10 | |
| EV/EBITDA | -53.45 | -31.44 | -19.12 | -14.34 | -9.21 | -27.34 | -32.72 | -25.29 | 0.01 | -0.21 | -0.70 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-9.81
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $10.1M |
| Net Income | -$17.0M |
| EPS | $-3.40 |
| # Analysts (EPS) | 1 |